All News
Adalimumab Withdrawal in Uveitis Patients
Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown recurrence of uveitis, arthritis, or both, when the disease was previously controlled on ADA.
Read Article
Weak Data (1.24.2025)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com, and features Dr. Charity Dean, the Keynote speaker at RheumNow Live 2025, and why she is an inspiration.
Read Article
Honoring Dr. Dafna Gladman
In December 2024, Dr. Dafna Gladman was appointed an officer of the Order of Canada by the Governor General. Established in 1967, the Order is one of Canada's top civilian honors, recognizing individuals whose achievements and service impact… https://t.co/Qv2uigX4sl https://t.co/uRsADqAZDq
Dr. John Cush RheumNow ( View Tweet)
Getting to Remission - Without Biologics
Analysis of data from two early rheumatoid arthritis (ERA) cohorts shows remission in RA is primarily seen in those who do not require biologic DMARDs (bDMARDs), while those needing bDMARDs are less apt to achieve remission.… https://t.co/K1gUdEhk1n https://t.co/PHQafKPHpB
Dr. John Cush RheumNow ( View Tweet)
French cross-sectional study of pts on stable sc MTX x several yrs. Examined MTX polyglutamates (MTX-PGs) & disease activity in 34 RA pts (25 remission). + correlation between RA remission & high MTX-PG3 levels in pts w/ BMI <25. BMI may limit utility of PG3 levels… https://t.co/uped4oMkut https://t.co/4fmnDVHYYb
Dr. John Cush RheumNow ( View Tweet)
Palmar fasciitis & polyarthritis syndrome (PFPAS). JAMA case 50yoM w/ progressive hand swelling, stiffness, thickening, erythema, hepato-splenomegaly. Skin Bx dermal fibrous tissue. WBC 152k, LDH 889, lead to CML dx made by BM Fx (myeloid-erythroid ratio 21 w/ myeloblasts). +… https://t.co/xtHbzAioss https://t.co/RfMrfntFtb
Dr. John Cush RheumNow ( View Tweet)
Cardiovascular Risk in Cutaneous Lupus Erythematosus
A retrospective study of cutaneous lupus erythematosus (CLE) patients finds an increased risk of atherosclerotic cardiovascular disease (ASCVD) on par with systemic lupus patients.
https://t.co/QimKD9klM2 https://t.co/2Yb0tWoOB0
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 11 studies shows that curcumin (tumeric) can reduce pain, muscle damage and inflammation in athletes following vigorous physical exercise. "pre- and post-exercise curcumin consumption.. assoc w/ better outcomes in muscle recovery, pain & antioxidant capacity"… https://t.co/FZE2ugvvPK
Dr. John Cush RheumNow ( View Tweet)
Head-to-Head Clinical Trials
https://t.co/tt8uLuLiV2 https://t.co/BvWxCGGN5V
Dr. John Cush RheumNow ( View Tweet)
Lung Involvement in Still's Disease
A multicentre registry observational study assessed lung involvement in a cohort of Still’s disease patients, affirming pleuritis as most common and that parenchymal lung inflammatory disease is very uncommon in both children and adults.… https://t.co/rGYEgCeUDA https://t.co/fdUGvfU8HH
Dr. John Cush RheumNow ( View Tweet)
“Nothing in all the world is more dangerous than sincere ignorance and conscientious stupidity.”
- Martin Luther King
(Isnt that when someone says “I don’t know and I don’t care”) https://t.co/ZDwyyhX9XT
Dr. John Cush RheumNow ( View Tweet)
post hoc analysis of 4 registration trials of pegloticase, show rates of MACE and Thromboembolic Events were Infrequent (<1.5%; 35.4 events/1000 PY), similar to general gout population (31.7 events/1000 person-years) https://t.co/v6ZqtL4yB2 https://t.co/NA0j20Oew2
Dr. John Cush RheumNow ( View Tweet)
Worldwide, it is estimated that arthralgia treatments cost USD 4.7 Billion in 2024 and is estimated to reach USD 9.0 Billion by 2035. https://t.co/DYnbhpLAhr https://t.co/sKR8sssKNx
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - ANA Negative Lupus
Pregnant ANA negative SLE (?) patients with Sjogrens and FM - what to do?
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6… https://t.co/RyCdiadn4H https://t.co/EvWcQ6KIxQ
Links:
Dr. John Cush RheumNow ( View Tweet)
French cross-sectional study of pts on stable sc MTX x several yrs. Examined MTX polyglutamates (MTX-PGs) & disease activity in 34 RA pts (25 remission). + correlation between RA remission & high MTX-PG3 levels in pts w/ BMI <25. BMI may limit utility of PG3 levels… https://t.co/scFzVy7hhA https://t.co/sUQUHFbhaG
Dr. John Cush RheumNow ( View Tweet)
“If I cannot do great things, I can do small things in a great way.”
- Martin Luther King https://t.co/2ixHPDdN1q
Dr. John Cush RheumNow ( View Tweet)
Palmar fasciitis & polyarthritis syndrome (PFPAS). JAMA case 50yoM w/ progressive hand swelling, stiffness, thickening, erythema, hepato-splenomegaly. Skin Bx dermal fibrous tissue. WBC 152k, LDH 889, lead to CML dx made by BM Fx (myeloid-erythroid ratio 21 w/ myeloblasts). +… https://t.co/7gj3mvOSqs https://t.co/56tLd1jsNf
Dr. John Cush RheumNow ( View Tweet)
Rheum to Travel
Meeting new people is a key benefit of attending conferences. At one symposium, I met a unique rheumatologist, Holly Bastian, MD, who practices without being tied to one place. As a nomadic rheumatologist, she spreads her skills and knowledge to areas needing… https://t.co/maONMwlL72 https://t.co/CHsHb6FnMG
Dr. John Cush RheumNow ( View Tweet)
Cardiovascular Risk in Cutaneous Lupus Erythematosus
A retrospective study of cutaneous lupus erythematosus (CLE) patients finds an increased risk of atherosclerotic cardiovascular disease (ASCVD) on par with systemic lupus patients.
https://t.co/3gEkFBK8wc https://t.co/kagpp7w7nE
Dr. John Cush RheumNow ( View Tweet)
Korean Biologics (KOBIO) registry showed SpA pts have higher risk of infection. 2,129 AS pts (7108 PY FU) most common was respiratory infx (26/1000 PY), followed by herpes zoster (6/1000 PY) Risk includes age, ischemic CV Dz, diabetes, CKD, peripheral arthritis.… https://t.co/0j1fH7OymW https://t.co/gqa1csylsn
Dr. John Cush RheumNow ( View Tweet)